ResMed operating in the digital health space has completed the acquisition of Ectosense, a cloud-connected home sleep test (HST) device that can help millions of people with undiagnosed sleep apnea get the treatment they need – and raise general awareness of the disease.

ResMed has been a minority investor in Ectosense since July 2020.

Ectosense will operate within ResMed’s Sleep and Respiratory Care business. The transaction is not material to ResMed’s consolidated financial results and its financial terms were not disclosed.

 “In developing markets, we need to make sleep tests affordable, accessible and easy to use,” said Justin Leong, ResMed president of Asia and Latin America. “Ectosense’s clinically validated, consumer-friendly devices will enable us to help millions of people in many markets improve their sleep and overall health. We’re excited to welcome Ectosense’s life-changing team to the ResMed family.” 

“ResMed has the global reach and passionate ambition to help increase patient access to Ectosense’s proven diagnostic solution and a path to better sleep and overall health,” said Frederik Massie, chief technology officer and co-founder of Ectosense. “

Ectosense’s FDA-approved NightOwl is sold in the United States, Australia, New Zealand, India, and parts of Europe. ResMed has distributed NightOwl in Australia, New Zealand, and India since 2020 under the brand “ResMed onesleeptest”